Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Cartesian Therapeutics (RNAC) Shares Outstanding (Diluted Average) (2019 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Shares Outstanding (Diluted Average) for 8 consecutive years, with $26.9 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) rose 3.68% year-over-year to $26.9 million; the TTM value through Mar 2026 reached $26.9 million, up 3.68%, while the annual FY2025 figure was $26.0 million, 49.63% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $26.9 million in Q1 2026 for Cartesian Therapeutics, up from $26.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $148.5 million in Q2 2022 and bottomed at $5.1 million in Q1 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $45.8 million, with a median of $25.9 million recorded in 2025.
  • Year-over-year, Shares Outstanding (Diluted Average) tumbled 96.56% in 2023 and then surged 378.44% in 2025.
  • Cartesian Therapeutics' Shares Outstanding (Diluted Average) stood at $145.9 million in 2022, then plummeted by 96.46% to $5.2 million in 2023, then skyrocketed by 235.72% to $17.4 million in 2024, then surged by 49.63% to $26.0 million in 2025, then increased by 3.4% to $26.9 million in 2026.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $26.9 million, $26.0 million, and $26.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.